Stock data
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL) reported net income of -US$38.18M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$48.27M | -US$38.18M | — |
| 2024 | — | — | -US$33.37M | -US$55.18M | — |
| 2023 | — | — | -US$38.39M | -US$37.94M | — |
| 2022 | US$0.12M | — | -US$34.72M | -US$18.79M | — |
| 2021 | US$0.12M | — | -US$25.73M | -US$36.12M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$38.91M | — |
| 2026-03-31 | — | -US$8.86M | — |
| 2025-12-31 | — | -US$29.50M | — |
| 2025-09-30 | — | -US$11.27M | — |
| 2025-06-30 | — | -US$4.80M | — |
| 2025-03-31 | — | US$7.38M | — |
| 2024-12-31 | — | -US$14.07M | — |
| 2024-09-30 | — | -US$10.65M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.